Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801–21.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Pardanani A. Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval. Blood Cancer J. 2024;14:47.

Article  PubMed  PubMed Central  Google Scholar 

Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica. 2023;108:2919–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129:1823–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4:4282–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, et al. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia. 2018;32:1035–8.

Article  CAS  PubMed  Google Scholar 

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017;35:3844–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5:e73–e81.

Article  PubMed  Google Scholar 

Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401:269–80.

Article  CAS  PubMed  Google Scholar 

Perez-Lamas L, Diaz AS, Delgado RG, Alvarez-Larran A, Senin MA, Mora E, et al. Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study. Blood Cancer J. 2025;15:67.

Article  PubMed  PubMed Central  Google Scholar 

Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda J-C, Bose P, Döhner K, et al. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024;144:1813–20.

Article  CAS  PubMed  Google Scholar 

Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, et al. MoReLife—real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Ann Hematol. 2024;103:4065–77.

Article  CAS  PubMed  Google Scholar 

Rampotas A, Torre E, Carter-Brzezinski L, Duminuco A, Cadman-Davies L, Chee A, et al. Real world efficacy and safety of momelotinib for myelofibrosis: evaluation of a UK-wide study confirms 40% anaemia response rate in a non-clinical trial cohort. Blood. 2024;144:1804.

Article  Google Scholar 

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.

Article  CAS  PubMed  Google Scholar 

Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023;7:5835–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdelmagid M, Palmer JM, Al-Kali A, Hefazi M, Foran J, Begna KH, et al. Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials. Haematologica. 2025. https://doi.org/10.3324/haematol.2025.287576.

Article  PubMed  Google Scholar 

Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, et al. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. Am J Hematol. 2023;98:282–9.

Article  CAS  PubMed  Google Scholar 

Gangat N, McCullough K, Al-Kali A, Begna KH, Patnaik MM, Litzow MR, et al. Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: a real-world experience. Br J Haematol. 2022;198:e54–e8.

Article  CAS  PubMed  Google Scholar 

Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, et al. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023;13:3.

Article  PubMed  PubMed Central  Google Scholar 

Gangat N, Tefferi A. Emerging pathogenetic mechanisms and new drugs for anemia in myelofibrosis and myelodysplastic syndromes. Am J Hematol. 2025. https://doi.org/10.1002/ajh.27659.

Article  PubMed  PubMed Central  Google Scholar 

Gerds AT, Harrison C, Kiladjian J-J, Mesa R, Vannucchi AM, Komrokji R, et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024;8:4511–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison C, Chee LCY, Devos T, Fox ML, Iurlo A, Palandri F, et al. Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis from the ongoing phase 2 restore trial. Blood. 2024;144:997.

Article  Google Scholar 

Gangat N, Foran JM, Halpern AB, Rampal R, Bose P, Hexner EO, et al. A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia. Blood. 2024;144:657.

Article  Google Scholar